Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR) - PubMed (original) (raw)
Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR)
E Ferrannini et al. J Clin Invest. 1997.
Abstract
Insulin resistance and insulin hypersecretion are established features of obesity. Their prevalence, however, has only been inferred from plasma insulin concentrations. We measured insulin sensitivity (as the whole-body insulin-mediated glucose uptake) and fasting posthepatic insulin delivery rate (IDR) with the use of the euglycemic insulin clamp technique in a large group of obese subjects in the database of the European Group for the Study of Insulin Resistance (1,146 nondiabetic, normotensive Caucasian men and women aged 18-85 yr, with a body mass index (BMI) ranging from 15 to 55 kg.m-2). Insulin resistance, defined as the lowest decile of insulin sensitivity in the lean subgroup (608 subjects with a mean BMI of 29 kg.m-2). Insulin sensitivity declined linearly with BMI at an age- and sex-adjusted rate of 1.2 micromol.min-1.kg FFM-1 per BMI unit (95% confidence intervals = 1.0-1.4). Insulin hypersecretion, defined as the upper decile of IDR, was significantly (P<0.0001) more prevalent (38%) than insulin resistance in the obese group. In the whole dataset, IDR rose as a function of both BMI and insulin resistance in a nonlinear fashion. Neither the waist circumference nor the waist-to-hip ratio, indices of body fat distribution, was related to insulin sensitivity after adjustment for age, gender, and BMI; both, however, were positively associated (P<0.001) with insulin hypersecretion, particularly in women. In nondiabetic, normotensive obese subjects, the prevalence of insulin resistance is relatively low, and is exceeded by the prevalence of insulin hypersecretion, particularly in women with central obesity. In the obese with preserved insulin sensitivity, risk for diabetes, cardiovascular risk, and response to treatment may be different than in insulin resistant obesity.
Similar articles
- beta-cell function in morbidly obese subjects during free living: long-term effects of weight loss.
Camastra S, Manco M, Mari A, Baldi S, Gastaldelli A, Greco AV, Mingrone G, Ferrannini E. Camastra S, et al. Diabetes. 2005 Aug;54(8):2382-9. doi: 10.2337/diabetes.54.8.2382. Diabetes. 2005. PMID: 16046305 - Independent influence of age on basal insulin secretion in nondiabetic humans. European Group for the Study of Insulin Resistance.
Iozzo P, Beck-Nielsen H, Laakso M, Smith U, Yki-Järvinen H, Ferrannini E. Iozzo P, et al. J Clin Endocrinol Metab. 1999 Mar;84(3):863-8. doi: 10.1210/jcem.84.3.5542. J Clin Endocrinol Metab. 1999. PMID: 10084562 - Effect of obesity and insulin resistance on resting and glucose-induced thermogenesis in man. EGIR (European Group for the Study of Insulin Resistance).
Camastra S, Bonora E, Del Prato S, Rett K, Weck M, Ferrannini E. Camastra S, et al. Int J Obes Relat Metab Disord. 1999 Dec;23(12):1307-13. doi: 10.1038/sj.ijo.0801072. Int J Obes Relat Metab Disord. 1999. PMID: 10643689 - beta-cell function in obesity: effects of weight loss.
Ferrannini E, Camastra S, Gastaldelli A, Maria Sironi A, Natali A, Muscelli E, Mingrone G, Mari A. Ferrannini E, et al. Diabetes. 2004 Dec;53 Suppl 3:S26-33. doi: 10.2337/diabetes.53.suppl_3.s26. Diabetes. 2004. PMID: 15561918 Review. - Physiological and metabolic consequences of obesity.
Ferrannini E. Ferrannini E. Metabolism. 1995 Sep;44(9 Suppl 3):15-7. doi: 10.1016/0026-0495(95)90313-5. Metabolism. 1995. PMID: 7674910 Review.
Cited by
- β-Cell Heterogeneity and Plasticity.
Yong HJ, Wang YJ. Yong HJ, et al. Adv Anat Embryol Cell Biol. 2024;239:57-90. doi: 10.1007/978-3-031-62232-8_3. Adv Anat Embryol Cell Biol. 2024. PMID: 39283482 Review. - Machine learning allows robust classification of visceral fat in women with obesity using common laboratory metrics.
Palmieri F, Akhtar NF, Pané A, Jiménez A, Olbeyra RP, Viaplana J, Vidal J, de Hollanda A, Gama-Perez P, Jiménez-Chillarón JC, Garcia-Roves PM. Palmieri F, et al. Sci Rep. 2024 Jul 27;14(1):17263. doi: 10.1038/s41598-024-68269-y. Sci Rep. 2024. PMID: 39068287 Free PMC article. - The Triglyceride/HDL Ratio as a Surrogate Biomarker for Insulin Resistance.
Baneu P, Văcărescu C, Drăgan SR, Cirin L, Lazăr-Höcher AI, Cozgarea A, Faur-Grigori AA, Crișan S, Gaiță D, Luca CT, Cozma D. Baneu P, et al. Biomedicines. 2024 Jul 5;12(7):1493. doi: 10.3390/biomedicines12071493. Biomedicines. 2024. PMID: 39062066 Free PMC article. Review. - Location Matters: Mitochondrial Arginase 2 as a Treatment for Metabolic Disease?
Stefkovich M, Titchenell PM. Stefkovich M, et al. Cell Mol Gastroenterol Hepatol. 2024;17(5):883-884. doi: 10.1016/j.jcmgh.2024.02.013. Epub 2024 Mar 10. Cell Mol Gastroenterol Hepatol. 2024. PMID: 38471656 Free PMC article. No abstract available. - Effect of physical activity levels on blood lipids, insulin resistance, and adipokines in children with obesity.
Sohn S, Lee JH, Joung H, Lee M, Ha MS. Sohn S, et al. Phys Act Nutr. 2023 Dec;27(4):34-40. doi: 10.20463/pan.2023.0035. Epub 2023 Dec 31. Phys Act Nutr. 2023. PMID: 38297474 Free PMC article.
References
- Metabolism. 1990 May;39(5):452-9 - PubMed
- Metabolism. 1991 Jan;40(1):101-4 - PubMed
- J Clin Invest. 1991 Jul;88(1):168-73 - PubMed
- Scand J Clin Lab Invest. 1991 May;51(3):245-53 - PubMed
- Eur J Clin Invest. 1991 Jun;21(3):280-7 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous